Bora Pharmaceuticls (BORAY) Stock Price, News & Analysis
Price Move History
- Daily moves over 5%
- 17 44 sessions, January 22, 2026 to October 1, 2026
- Largest daily move
- -65% close of October 1, 2026
- 1-month change
- -10.6% closing prices, August 31, 2026 to October 1, 2026
Company Description
Bora Pharmaceuticals Co., Ltd. (BORAY) operates as a pharmaceutical manufacturing company and contract development and manufacturing organization serving commercial drug products and pharmaceutical partners. The company is associated with Taiwan-listed shares under 6472.TW and an OTCQX-traded security under BORAY. Its disclosed operations include global commercial manufacturing, development support, and product supply services for established pharmaceutical products.
Bora’s CDMO business includes manufacturing work for pharmaceutical partners across multiple therapeutic areas. At its Mississauga facility, which Bora purchased from GSK in 2020, the company provides end-to-end manufacturing services for commercial product lines and individual products used in areas that include infectious disease, mental health, dermatology, migraine, and other conditions. The company’s manufacturing network also includes an oral solid dose site in Maple Grove, Minnesota, used within its broader pharmaceutical production infrastructure.
Through Upsher-Smith Laboratories, LLC, a Bora subsidiary, the company also participates in the U.S. prescription pharmaceutical market. Upsher-Smith’s activities include launches of generic and branded prescription products, differentiated dosage forms, and patient and healthcare professional support resources tied to specific medicines. Its disclosed products include KYMBEE (deflazacort) Tablets, indicated for Duchenne muscular dystrophy in patients 5 years of age and older, and Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, a generic version of Ciprodex.
Bora’s business model combines contract manufacturing services for external pharmaceutical companies with product commercialization through its operating subsidiary. Its disclosures emphasize commercial-scale manufacturing, oral solid dose capabilities, product launches, portfolio diversification, and access-support programs connected to prescribed therapies.
Stock Performance
Bora Pharmaceuticls (BORAY) closed at $2.45 on October 1, 2026. In the month to October 1, 2026, the price lost 10.6%.
BORAY Metrics & Rankings
Price returns through October 1, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Bora Pharmaceuticls has 5 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 2 with negative movement. Key topics include clinical trial. View all BORAY news →
SEC Filings
Short Interest History
Short interest in Bora Pharmaceuticls (BORAY) currently stands at 34 shares, a new position with no short interest reported in the previous period. Since February 2026, short interest has decreased by 84.2%.
Days to Cover History
Days to cover for Bora Pharmaceuticls (BORAY) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume.
BORAY Company Profile & Sector Positioning
Bora Pharmaceuticls (BORAY) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the OTC.
Investors comparing BORAY often look at related companies in the same sector, including NIKA Pharmaceuticals Inc (NIKA), Verano Holdings Corp (VRNO), Vireo Growth Inc (VREOF), Elite Pharms Inc (ELTP), and Auxly Cnnabis Grp Inc (CBWTF). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate BORAY's relative position within its industry.